Comments
Loading...

Day One Biopharmaceutical

DAWNNASDAQ
$15.54
-0.11-0.70%
Last update: 11:15 AM
15 minutes delayed
Consensus Rating1
Overweight
Highest Price Target1
$44.00
Lowest Price Target1
$9.00
Consensus Price Target1
$34.63

want to know what
the Bulls & Bears Say?

Day One Biopharmaceutical (NASDAQ:DAWN) Stock, Analyst Ratings, Price Targets, Forecasts

Day One Biopharmaceuticals Inc has a consensus price target of $34.63 based on the ratings of 9 analysts. The high is $44 issued by Goldman Sachs on February 27, 2024. The low is $9 issued by B of A Securities on April 25, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, HC Wainwright & Co., and Needham on July 8, 2024, June 20, 2024, and June 19, 2024, respectively. With an average price target of $37.67 between Piper Sandler, HC Wainwright & Co., and Needham, there's an implied 142.39% upside for Day One Biopharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Apr
0
0
0
0
May
0
0
0
0
Jun
1
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
HC Wainwright & Co.
Needham
JP Morgan
Goldman Sachs

1calculated from analyst ratings

Analyst Ratings for Day One Biopharmaceutical

Buy NowGet Alert
07/08/2024Buy Now157.4%Piper Sandler
Joseph Catanzaro
$40 → $40MaintainsOverweightGet Alert
06/20/2024Buy Now157.4%HC Wainwright & Co.
Andres Maldonado
$40 → $40ReiteratesBuy → BuyGet Alert
06/19/2024Buy Now112.36%Needham
Ami Fadia
$33 → $33ReiteratesBuy → BuyGet Alert
05/07/2024Buy Now112.36%Needham
Ami Fadia
→ $33ReiteratesBuy → BuyGet Alert
05/07/2024Buy Now157.4%HC Wainwright & Co.
Andres Maldonado
$50 → $40MaintainsBuyGet Alert
04/25/2024Buy Now112.36%Needham
Ami Fadia
→ $33ReiteratesBuy → BuyGet Alert
04/24/2024Buy Now221.75%HC Wainwright & Co.
Andres Maldonado
→ $50ReiteratesBuy → BuyGet Alert
04/24/2024Buy Now112.36%Needham
Ami Fadia
$30 → $33MaintainsBuyGet Alert
04/22/2024Buy Now131.66%JP Morgan
Anupam Rama
$32 → $36MaintainsOverweightGet Alert
03/26/2024Buy Now157.4%Piper Sandler
Joseph Catanzaro
$40 → $40MaintainsOverweightGet Alert
02/28/2024Buy Now157.4%Piper Sandler
Joseph Catanzaro
$45 → $40MaintainsOverweightGet Alert
02/27/2024Buy Now183.14%Goldman Sachs
Andrea Tan
$50 → $44MaintainsBuyGet Alert
02/27/2024Buy NowOppenheimer
Matthew Biegler
ReiteratesPerform → PerformGet Alert
11/07/2023Buy Now125.23%Wedbush
Robert Driscoll
$39 → $35MaintainsOutperformGet Alert
11/07/2023Buy Now118.79%Needham
Ami Fadia
→ $34ReiteratesBuy → BuyGet Alert
09/12/2023Buy Now144.53%Wedbush
Robert Driscoll
→ $38ReiteratesOutperform → OutperformGet Alert
09/12/2023Buy Now118.79%Needham
Ami Fadia
→ $34ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now118.79%Needham
Ami Fadia
→ $34Reiterates → BuyGet Alert
08/08/2023Buy Now247.49%Goldman Sachs
Andrea Tan
$63 → $54MaintainsBuyGet Alert
08/08/2023Buy Now221.75%HC Wainwright & Co.
Andres Maldonado
→ $50ReiteratesBuy → BuyGet Alert
06/05/2023Buy Now144.53%Wedbush
Robert Driscoll
→ $38ReiteratesOutperform → OutperformGet Alert
06/05/2023Buy Now157.4%Needham
Ami Fadia
→ $40ReiteratesBuy → BuyGet Alert
06/05/2023Buy Now221.75%HC Wainwright & Co.
Andres Maldonado
$45 → $50MaintainsBuyGet Alert
05/18/2023Buy Now189.58%HC Wainwright & Co.
Andres Maldonado
→ $45ReiteratesBuy → BuyGet Alert
05/08/2023Buy Now157.4%Needham
Ami Fadia
$44 → $40MaintainsBuyGet Alert
05/02/2023Buy Now183.14%Needham
Ami Fadia
→ $44Reiterates → BuyGet Alert
04/25/2023Buy Now-42.08%B of A Securities
Alec Stranahan
$34 → $9DowngradeBuy → UnderperformGet Alert
04/05/2023Buy Now183.14%Needham
Ami Fadia
$48 → $44MaintainsBuyGet Alert
03/07/2023Buy Now208.88%Needham
Ami Fadia
→ $48Reiterates → BuyGet Alert
03/07/2023Buy Now189.58%HC Wainwright & Co.
Andres Maldonado
→ $45Reiterates → BuyGet Alert
02/08/2023Buy Now157.4%Capital One
Naureen Quibria
→ $40Initiates → OverweightGet Alert
02/03/2023Buy NowOppenheimer
Matthew Biegler
Initiates → PerformGet Alert
01/09/2023Buy Now298.97%Goldman Sachs
Andrea Tan
$45 → $62MaintainsBuyGet Alert
01/09/2023Buy Now189.58%Piper Sandler
Joseph Catanzaro
$40 → $45MaintainsOverweightGet Alert
01/09/2023Buy Now189.58%HC Wainwright & Co.
Andres Maldonado
$35 → $45MaintainsBuyGet Alert
12/15/2022Buy Now125.23%HC Wainwright & Co.
Andres Maldonado
→ $35Initiates → BuyGet Alert
12/14/2022Buy Now157.4%Needham
Ami Fadia
→ $40Initiates → BuyGet Alert
12/05/2022Buy Now189.58%Goldman Sachs
Andrea Tan
→ $45Initiates → BuyGet Alert
12/01/2022Buy Now118.79%B of A Securities
Alec Stranahan
→ $34Initiates → BuyGet Alert
06/21/2022Buy Now157.4%Piper Sandler
Joseph Catanzaro
$35 → $40MaintainsOverweightGet Alert
06/14/2022Buy Now125.23%Wedbush
Robert Driscoll
$32 → $35MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Day One Biopharmaceutical (DAWN) stock?

A

The latest price target for Day One Biopharmaceutical (NASDAQ:DAWN) was reported by Piper Sandler on July 8, 2024. The analyst firm set a price target for $40.00 expecting DAWN to rise to within 12 months (a possible 157.40% upside). 20 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Day One Biopharmaceutical (DAWN)?

A

The latest analyst rating for Day One Biopharmaceutical (NASDAQ:DAWN) was provided by Piper Sandler, and Day One Biopharmaceutical maintained their overweight rating.

Q

When was the last upgrade for Day One Biopharmaceutical (DAWN)?

A

There is no last upgrade for Day One Biopharmaceutical

Q

When was the last downgrade for Day One Biopharmaceutical (DAWN)?

A

The last downgrade for Day One Biopharmaceuticals Inc happened on April 25, 2023 when B of A Securities changed their price target from $34 to $9 for Day One Biopharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Day One Biopharmaceutical (DAWN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.

Q

Is the Analyst Rating Day One Biopharmaceutical (DAWN) correct?

A

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a maintained with a price target of $40.00 to $40.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $15.54, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch